GlassScriptPhysician profile
Devin G Trevor
NPI 1073514345
$4,942.12
in general payments reported to CMS, 2019-2025
35 companies · $709 in 2025
The $709 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $82.73 · 2021: $854 · 2022: $1,335 · 2023: $703 · 2024: $879 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aspira Women'S Health INC | $1,084.71 | 2020-2024 | Ova1 |
| Applied Medical Resources Corporation | $603.60 | 2021-2022 | |
| Biogen, INC. | $468.20 | 2024-2025 | Zurzuvae |
| Abbvie INC. | $394.11 | 2019-2025 | |
| Organon LLC | $302.26 | 2021-2025 | Nexplanon |
| Astellas Pharma US INC | $281.00 | 2023-2025 | Veozah |
| Exeltis, USA INC. | $257.96 | 2021-2025 | Slynd |
| Hologic Sales and Service, LLC | $195.94 | 2021-2024 | Aptima, Acessa Provu System |
| Allergan, INC. | $171.41 | 2019 | |
| Pfizer INC. | $130.24 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $115.99 | 2023-2025 | |
| Myovant Sciences INC. | $114.59 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $103.93 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $97.76 | 2019-2022 | |
| Caldera Medical, INC | $93.15 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $69.20 | 2020-2025 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $55.13 | 2019-2023 | Gardasil 9 |
| Millicent US INC | $47.44 | 2025 | Femlyv, Intrarosa |
| Meditrina | $41.21 | 2023-2024 | |
| Novo Nordisk INC | $29.63 | 2021-2024 | Wegovy |
| Amag Pharmaceuticals, INC. | $29.05 | 2019 | |
| Smith+Nephew, INC. | $28.35 | 2022 | |
| Evofem Biosciences, INC. | $25.55 | 2021 | |
| Agile Therapeutics, INC. | $23.59 | 2022 | |
| Duchesnay USA Incorporated | $18.40 | 2019 | |
| Exact Sciences Corporation | $18.11 | 2025 | Cologuard Collection Kit |
| Sage Therapeutics, LLC | $17.84 | 2019 | |
| Aspen Surgical Products, INC. | $17.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.85 | 2019 | |
| Lilly USA, LLC | $16.39 | 2025 | Zepbound |
| Vertex Pharmaceuticals Incorporated | $16.22 | 2025 | |
| Shield Therapeutics INC | $16.12 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $15.43 | 2022 | |
| Therapeuticsmd, INC. | $13.73 | 2021 | |
| Amgen INC. | $12.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Trevor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.